Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors

Respirology

Volumn 19, Issue 5, 2014, Pages 700-706

  Zimmermann, Gregor S ^a   Von Wulffen, Werner ^a   Huppmann, Patrick ^a   Meis, Tobias ^a   Ihle, Franziska ^a   Geiseler, Jens ^c   Leuchte, Hanno H ^b   Tufman, Amanda ^a   Behr, Juergen ^a,c   Neurohr, Claus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Department of Internal Medicine II Neuwittelsbach Hospital ^*  (Germany)

^c ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

Author keywords

idiopathic pulmonary fibrosis; interstitial lung disease; phosphodiesterase 5 inhibitor; pulmonary fibrosis; pulmonary hypertension

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BRAIN NATRIURETIC PEPTIDE; PHOSPHODIESTERASE V INHIBITOR; PIRFENIDONE; PREDNISONE; SILDENAFIL; TADALAFIL; CARBOLINE DERIVATIVE; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONAMIDE;

ADULT; ALLERGIC PNEUMONITIS; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HEART CATHETERIZATION; HEART INDEX; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT DURATION; WALKING; AGED; BLOOD; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; HEMODYNAMICS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PILOT STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARBOLINES; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PHOSPHODIESTERASE 5 INHIBITORS; PILOT PROJECTS; PIPERAZINES; PURINES; RESPIRATORY FUNCTION TESTS; SULFONAMIDES; WALKING;

EID: 84903118272     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12294     Document Type: Article

References (29)

1. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF,. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-752.
2. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, Pochettino A, Kotloff RM,. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am. J. Respir. Crit. Care Med. 2003; 167: 735-740. (Pubitemid 36801751)
3. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD,. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131: 657-663. (Pubitemid 46446854)
4. Behr J, Ryu JH,. Pulmonary hypertension in interstitial lung disease. Eur. Respir. J. 2008; 31: 1357-1367.
5. Judge EP, Fabre A, Adamali HI, Egan JJ,. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur. Respir. J. 2012; 40: 93-100.
6. Hamada K, Nagai S, Tanaka S, Handa T, Shigematsu M, Nagao T, Mishima M, Kitaichi M, Izumi T,. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131: 650-656. (Pubitemid 46446853)
7. Leuchte HH, Baumgartner RA, Nounou ME, Vogeser M, Neurohr C, Trautnitz M, Behr J,. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 744-750.
8. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q,. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341: 1550-1554. (Pubitemid 23170459)
9. Nathan SD, Noble PW, Tuder RM,. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am. J. Respir. Crit. Care Med. 2007; 175: 875-880. (Pubitemid 46684695)
10. Patel NM, Lederer DJ, Borczuk AC, Kawut SM,. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007; 132: 998-1006.
11. Mura M, Anraku M, Yun Z, McRae K, Liu M, Waddell TK, Singer LG, Granton JT, Keshavjee S, de Perrot M,. Gene expression profiling in the lungs of patients with pulmonary hypertension associated with pulmonary fibrosis. Chest 2012; 141: 661-673.
12. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H,. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am. J. Physiol. 1994; 266: L536-543.
13. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA,. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131: 897-899. (Pubitemid 46446887)
14. Corte TJ, Gatzoulis MA, Parfitt L, Harries C, Wells AU, Wort SJ,. The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. Respirology 2010; 15: 1226-1232.
15. Han MK, Bach DS, Hagan P, Yow E, Flaherty K, Toews GB, Anstrom KJ, Martinez FJ,. Sildenafil preserves exercise capacity in IPF patients with right ventricular dysfunction. Chest 2013.
16. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F,. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900. (Pubitemid 35283832)
17. Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, Kolbe T, Schwaiblmair M, Behr J,. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J. Am. Coll. Cardiol. 2004; 43: 764-770. (Pubitemid 38296473)
18. McEvoy JD, Jones NL,. Arterialized capillary blood gases in exercise studies. Med. Sci. Sports 1975; 7: 312-315.
19. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC,. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur. Respir. J. Suppl. 1993; 16: 5-40.
20. Crapo RO, (writing author). ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166: 111-117. Available from http://www.thoracic.org/statements/resources/pft/sixminute.pdf (Pubitemid 34693972)
21. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788-824.
22. Jankowich MD, Rounds SI,. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest 2012; 141: 222-231.
23. Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, Grohe C, Gunther A, Halank M, Hammerl P, et al. Pulmonary hypertension due to chronic lung disease: updated recommendations of the cologne consensus conference 2011. Int. J. Cardiol. 2011; 154 (Suppl. 1): S45-53.
24. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW,. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N. Engl. J. Med. 2010; 363: 620-628.
25. Jackson RM, Glassberg MK, Ramos CF, Bejarano PA, Butrous G, Gomez-Marin O,. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung 2010; 188: 115-123.
26. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2005; 353: 2148-2157. (Pubitemid 41653106)
27. Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
28. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, Ryu JH,. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393-2399. (Pubitemid 41507585)
29. Thabut G, Mal H, Castier Y, Groussard O, Brugiere O, Marrash-Chahla R, Leseche G, Fournier M,. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J. Thorac. Cardiovasc. Surg. 2003; 126: 469-475. (Pubitemid 37048514)